USANA Health Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
USANA Health Sciences, Inc. (USNA) filed this Current Report on Form 8-K on July 23, 2024. The filing announces the Company's financial results for the second quarter ended June 29, 2024. The report incorporates by reference a press release and a "Management Commentary" document furnished as Exhibits 99.1 and 99.2.
Key Financial Metrics
The provided text serves as a cover document for the financial results and does not contain specific numerical data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the period ended June 29, 2024. Investors must refer to the attached Exhibits 99.1 and 99.2 for these figures.
Material Changes
This filing does not detail specific material changes versus the prior comparable period. It solely notifies the market of the release of Q2 2024 results and the availability of management commentary.
Guidance, Outlook, and Management Commentary
- Management Commentary: The Company announced it will post a document titled "Management Commentary" on its corporate website (www.usana.com).
- Conference Call: Company executives will hold a conference call with investors, broadcast via the World Wide Web and telephone. The call will feature brief remarks followed by a question-and-answer session.
- Regulation FD: The information disclosed under Item 2.02 and the attached exhibits are incorporated by reference under Item 7.01 for Regulation FD disclosure purposes.
Important Facts for Investor Verification
- Verify the specific Q2 2024 financial results (revenue, net income, EPS) in Exhibit 99.1 (Press Release).
- Review the "Management Commentary" in Exhibit 99.2 for detailed operational insights and forward-looking statements.
- Confirm the date and time of the investor conference call as detailed in the press release.
- Note that the information in this 8-K is furnished and not deemed "filed" for Section 18 liability purposes under the Exchange Act.